Daniel Fayard, MD
Epilepsy · Phoenix, AZNPI 1629414834
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.3% of the total across 173 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 21.6% — the pattern of someone who eats at a lot of different presentations.
Across 173 payments — averaging $44.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- SK Life Science, Inc.$2K
- Livanova USA, Inc.$1K
- UCB, Inc.$1K
- Neurelis, Inc.$602
- Neuropace, Inc.$585
- Jazz Pharmaceuticals Inc.$544
- plus $2K from 31 others
What the payments were for
- Speaking & faculty fees$3004%
- Travel & lodging$631%
- Food & beverage$7,36095%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| SK Life Science, Inc. | 21 | $1,669 |
| Livanova USA, Inc. | 20 | $1,075 |
| UCB, Inc. | 23 | $1,055 |
| Neurelis, Inc. | 9 | $602 |
| Neuropace, Inc. | 13 | $585 |
| Jazz Pharmaceuticals Inc. | 6 | $544 |
| Sunovion Pharmaceuticals Inc. | 12 | $323 |
| Medtronic | 3 | $315 |
| Amgen | 9 | $138 |
| Lilly USA, LLC | 8 | $132 |
| Argenx US, Inc. | 5 | $131 |
| Catalyst Pharmaceuticals, Inc. | 2 | $120 |
| E.r. Squibb & Sons, L.L.C. | 1 | $119 |
| Monteris Medical Corporation | 1 | $103 |
| AstraZeneca(2 entities) | 5 | $100 |
| Biocodex, Inc. | 1 | $85 |
| Eisai Inc. | 3 | $82 |
| Lundbeck LLC | 3 | $56 |
| Novartis | 3 | $49 |
| Johnson & Johnson | 2 | $41 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $37 |
| Sumitomo Pharma America, Inc. | 3 | $36 |
| Greenwich Biosciences, Inc. | 2 | $33 |
| Pacira Pharmaceuticals Incorporated | 1 | $31 |
| Teva Pharmaceuticals USA, Inc. | 2 | $27 |
| Amneal Pharmaceuticals LLC | 2 | $26 |
| TG Therapeutics, Inc. | 1 | $26 |
| Progenics Pharmaceuticals, Inc. | 1 | $24 |
| Avanir Pharmaceuticals, Inc. | 1 | $22 |
| Servier Pharmaceuticals LLC | 1 | $22 |
| Impel Pharmaceuticals Inc. | 1 | $21 |
| AbbVie | 1 | $17 |
| Tanabe Pharma America, Inc. | 1 | $16 |
| Boston Scientific | 1 | $16 |
| Biogen | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| Zyla Life Sciences, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS Therapy$300
- Epidiolex$300
- Fintepla$294
- Briviact$251
- XCOPRI$243
- VALTOCO$215
- SenSight$210
- Nayzilam$125
- APTIOM$120
- ZEPOSIA$119
- RNS System$109
- PERCEPT PC BRAINSENSE$105
- Neuroblate$103
How this compares
Too few epilepsy providers in Arizonato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AptiomEslicarbazepine Acetate | 32 | $56,820 |
| XcopriCenobamate | 28 | $42,364 |
| FycompaPerampanel | 17 | $21,599 |
| Lamotrigine ErLamotrigine | 30 | $17,122 |
| BriviactBrivaracetam | 11 | $16,294 |
| Levetiracetam | 127 | $5,018 |
| Lacosamide | 30 | $3,870 |
| Lamotrigine | 87 | $2,327 |
| Oxcarbazepine | 16 | $2,181 |
| Zonisamide | 49 | $1,472 |
| Divalproex Sodium | 23 | $992 |
| Gabapentin | 24 | $794 |
| Phenytoin Sodium Extended | 12 | $235 |
| Clonazepam | 21 | $187 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sunovion Pharmaceuticals Inc.Aptiom | $323 | $56,82032 claims |
| SK Life Science, Inc.Xcopri | $1,669 | $42,36428 claims |
| Eisai Inc.Fycompa | $82 | $21,59917 claims |
| UCB, Inc.Briviact | $1,055 | $16,29411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few epilepsy providers in Arizonaon file to place this against a meaningful peer group, so we don't.
Other epilepsy in Phoenix
- Ganesh MurthyPhoenix$8K
- Matthew HoerthPhoenix$3K
- Susan HermanPhoenix$3K
- David HarrisPhoenix$2K
- Courtney SchussePhoenix$1K
- Vladimir ShvartsPhoenix$1K
- Michael SteinPhoenix$635
- Kevin ChoiPhoenix$422
- Laura LehnhoffPhoenix$272
- Deana GazzolaPhoenix$236
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.